Myalgic encephalomyelitis/chronic fatigue syndrome from current evidence to new diagnostic perspectives through skeletal muscle and metabolic disturbances. — ME/CFS Atlas
Myalgic encephalomyelitis/chronic fatigue syndrome from current evidence to new diagnostic perspectives through skeletal muscle and metabolic disturbances.
Pietrangelo, Tiziana, Cagnin, Stefano, Bondi, Danilo et al. · Acta physiologica (Oxford, England) · 2024 · DOI
Quick Summary
This review examines what we know about ME/CFS by focusing on problems in muscles and how the body uses energy. Researchers looked at existing research to understand why ME/CFS causes severe tiredness and muscle problems. The authors suggest that studying muscle tissue more closely might help doctors diagnose ME/CFS better and develop new treatments.
Why It Matters
Understanding muscle and metabolic problems in ME/CFS is crucial because it could lead to reliable diagnostic tests and new treatments that don't currently exist. This review becomes especially important given the increased attention to ME/CFS following COVID-19, helping distinguish ME/CFS from long-COVID and clarifying the biological basis of the disease.
Observed Findings
Skeletal muscle tissue shows distinct abnormalities in ME/CFS patients including metabolic dysfunction and evidence of impaired energy production.
ME/CFS and long-COVID share overlapping clinical symptoms (particularly debilitating fatigue) but have different underlying etiologies.
Multiple hypotheses exist regarding ME/CFS pathophysiology, with no single unified mechanism yet established.
Muscle-based investigations offer novel opportunities for diagnosis distinct from current clinical assessment approaches.
Terminology debates surrounding ME/CFS nomenclature may be resolved through biological evidence from muscle and metabolic studies.
Inferred Conclusions
Skeletal muscle tissue represents a promising biomarker source for developing objective diagnostic criteria for ME/CFS.
Focusing research on muscle pathophysiology and metabolic disturbances may clarify the long-debated etiology of ME/CFS.
Systematic investigation of muscle dysfunction could lead to targeted therapeutic interventions beyond current symptomatic management.
Muscle-level evidence may help resolve the clinical and nosological distinction between ME/CFS and post-COVID conditions.
Remaining Questions
What specific muscle abnormalities are pathognomonic to ME/CFS versus shared with other post-viral conditions?
What This Study Does Not Prove
This review does not prove that muscle dysfunction is the sole cause of ME/CFS—it identifies it as a significant factor among multiple potential contributors. The study does not establish new diagnostic tests or treatments directly; rather, it identifies muscle tissue as a promising avenue for future research. As a review of existing evidence, it cannot generate new primary data and is limited by the methodological quality of previously published studies.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →